Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163473 · ClinicalTrials.gov registry record
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 63
- Enrollment target
NCT02163473: Completed study, sponsored by University of Florida.
NCT02163473 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02163473 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if a chemical marker in the blood, hypoxia-inducible factor (HIF-1 alpha), can be used to predict subject's hospital outcomes when the subject is diagnosed with sepsis. Sepsis is defined as either the presence of pathogenic organisms or their toxins in the blood and tissues. Sepsis is one of the most significant challenges in critical care medicine. The investigators propose that hypoxia-induced expression of HIF-1 alpha will correlate with the clinical features of Sepsis and in the future, HIF-1 alpha may be used as a biomarker in Sepsis.
Primary Outcome
Hypoxia-inducible factor will be measured at initial diagnosis (baseline) and 24 hours later in subjects with clinical presentation of sepsis and correlated with lactic acidosis.
Interventions
- PROCEDURE Septic patients
- PROCEDURE Healthy Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-06 |
What the finished NCT02163473 record still lists
NCT02163473 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Septic patients is the first listed.
NCT02163473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02163473 about?
NCT02163473 is a clinical study titled "Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock". The purpose of this research study is to determine if a chemical marker in the blood, hypoxia-inducible factor (HIF-1 alpha), can be used to predict subject's hospital outcomes when the subject is diagnosed with sepsis. Sepsis is defined as either the presence of pathogenic organisms or their toxins...
What is the current status of trial NCT02163473?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2013-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02163473?
The interventions under investigation include: Septic patients (PROCEDURE), Healthy Control (PROCEDURE).
Who is sponsoring clinical trial NCT02163473?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia